Sequenom reveals prenatal Down syndrome test data are "questionable"

For those who have been too distracted by swine flu to notice: shares of the biotech company Sequenom have plummeted by 77% after the company announced that the extremely promising initial results for its SEQureDx Down syndrome test - which is designed to detect Down syndrome fetuses using blood samples from pregnant women - were "questionable" and had been mishandled by employees.

GenomeWeb Daily News reports:


As of early February, Sequenom had released data on
its SEQureDx test from a total of 858 samples. It said that the
positive predictive value was 96.6 percent, and the negative predictive
value was 100 percent. But, the firm can no longer rely on that data.

"We are confident in the assay performance," [Sequenom CEO Harry] Stylli said during the
call. "It's fair to say that the high-level clinical performance that
we've disclosed to you is questionable."

Stylli said he was limited in what he could say in response to
questions about the incident, due to confidentiality agreements and the
investigation. "The data in question relates to data that goes back to
June -- the September and January releases of information -- I believe
that information is now suspect ... I can't really go into any of the
details because of the confidentiality considerations and because the
investigation is not complete," he said.

Here's Sequenom's share price over the last five days:

i-9a9abd5c68b20ec9a31e9c5a8703105e-sqnm_5day_nasdaq_090430.jpg

More like this

The Director of Loyola University Medical Center's clinical microbiology laboratory is reported as saying that rapid flu tests are a public health risk. Here's some of what he said and then my explanation as to why it is misleading or just plain wrong: Rapid influenza diagnostic tests used in…
Last week, striking Walmart workers and supporters of OUR Walmart converged on the company's shareholder meeting in Bentonville, Arkansas, calling for higher wages and better working conditions. Walmart employee Janet Sparks delivered a shareholder resolution that would have required senior…
by Elizabeth Grossman On August 28, 2008 at 10:53 p.m., a massive explosion and fire, caused by a runaway chemical reaction, ripped through the Bayer CropScience pesticide plant in Institute, West Virginia. It killed two workers and injured eight employees, two contractors, and six fire-fighters,…
There are multiple trials of swine flu vaccine in different countries and involving different subpopulations. Recent news strongly suggests that -- surprisingly -- a single dose of viral antigen (i.e., one injection) may be sufficient to raise antibody against swine flu to protective levels. There…

Not good for SQNM. But I thought they've been seeing good data for more than the past 6 months (though last year's data was in a small sample). I wish the report had more information--if the test is still good, then this is just bad for their credibility but hopefully shouldn't hurt them in the long run. Really wish there were more details available.

Wait never mind. I just read the press release on the company website and they are saying that all data released thus far about the DS test are in question.

Stock's going "down syndrome".

Lot of companies caught that bug lately.

By anomalous (not verified) on 30 Apr 2009 #permalink

It would be interesting to see who sold shares in the months before they released that information.

You can look up online who among the officers sold shares...The VP of prenatial dianostics sold $300K of shares at the end of March.

As far as I can tell from the site, no other officer ever sold nearly as many shares in years.

By swbarnes2 (not verified) on 08 May 2009 #permalink